D.E. Shaw & Co’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

D.E. Shaw & Co’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-489,613	Closed	-$11.8M	–	4812
2023 Q1	$11.8M	Sell	489,613 -653,687	-57%	-$8.2M	0.01%	1231
2022 Q4	$12.1M	Buy	1,143,300 +1,038,757	+994%	+$8.38M	0.01%	1285
2022 Q3	$471K	Buy	104,543 +46,400	+80%	+$211K	﹤0.01%	4073
2022 Q2	$233K	Buy	58,143 +7,361	+14%	+$34.9K	﹤0.01%	4481
2022 Q1	$372K	Buy	+50,782	New	+$304K	﹤0.01%	4539

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

D.E. Shaw & Co's PRVB Position: Q2 2023 in Review

D.E. Shaw & Co sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 489,613 shares — an estimated $11.8M sold.

D.E. Shaw & Co first reported a position in PRVB in Q1 2022 and held it in 5 quarters. The position peaked at $12.1M in Q4 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

D.E. Shaw & Co reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
D.E. Shaw & Co sold 489,613 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $11.8M.
D.E. Shaw & Co first reported a position in Provention Bio, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
D.E. Shaw & Co's Provention Bio, Inc. Common Stock position peaked at $12.1M in Q4 2022.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on D.E. Shaw & Co's 13F filing for Q2 2023, filed 14 Aug 2023.